文献速递头颈外科咽喉与嗓音

淋巴血管侵犯预测喉癌生存:国家数据库分析

Lymphovascular Invasion Predicts Survival in Laryngeal Cancer: A National Database Analysis.
PubMed 文献 · Laryngoscope · 2026-09-18

该研究基于国家数据库分析10,052例手术治疗的喉鳞状细胞癌患者,其中20.3%存在淋巴血管侵犯(LVI)。多变量Cox回归显示LVI独立关联更差的总生存(HR 1.22,95%CI 1.13-1.32,p<0.001),且在声门型和声门上型肿瘤中持续存在。

要点

  • LVI是喉鳞癌独立不良预后因素,与更差总生存相关。
  • LVI预后影响随时间变化,24个月后仍显著。
  • 有LVI患者术后放疗或放化疗较单纯手术生存更优。

核心结论

  • LVI是喉鳞状细胞癌手术患者的不良预后因素,与总生存下降独立相关,其预后影响随时间变化,纳入术后风险评估有助于指导辅助治疗选择和分层。

研究设计与样本

  • 回顾性队列研究,纳入10,052例接受根治性手术切除、无远处转移的成人喉鳞状细胞癌患者,排除术前放疗、全身治疗或非鳞状组织学患者;采用多变量Cox回归分析LVI与总生存的关联,调整人口学、合并症、分期、亚部位、手术切缘、机构类型和治疗方式。

主要发现

  • 共10,052例患者纳入,2037例(20.3%)存在LVI,平均随访70±46个月。
  • LVI独立关联更差的总生存(HR 1.22,95%CI 1.13-1.32,p<0.001)。
  • 声门型肿瘤中LVI关联更差总生存(HR 1.30,p=0.001),声门上型肿瘤中亦显著(HR 1.26,p<0.001)。
  • Landmark分析显示LVI在随访超过24个月后仍显著关联更差总生存(HR 1.18,p=0.001)。
  • 在LVI患者中,术后放疗(PORT)和术后放化疗(POCRT)较单纯手术与生存改善相关。

关键数值与推荐

  • LVI与更差总生存独立相关:HR 1.22(95%CI 1.13-1.32,p<0.001)。
  • 声门型肿瘤中LVI的HR为1.30(p=0.001),声门上型为1.26(p<0.001)。
  • 随访超过24个月后LVI仍显著关联更差总生存:HR 1.18(p=0.001)。

临床怎么用

  • 对喉鳞癌术后患者应常规评估LVI状态,将其纳入术后风险分层。
  • 存在LVI的患者可考虑术后放疗或术后放化疗以改善生存。

局限性

  • 原文未报告具体局限性内容。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Lymphovascular invasion (LVI) is routinely reported in laryngeal squamous cell carcinoma (LSCC), yet its independent prognostic significance and therapeutic implications remain uncertain. We evaluated the association between LVI and overall survival (OS) in a large cohort of surgically treated LSCC. METHODS: Adults with LSCC who underwent definitive surgical resection without distant metastases were included. Patients with preoperative radiotherapy, systemic therapy, or non-squamous histology were excluded. Multivariable Cox regression assessed the association between LVI and OS, adjusting for demographics, comorbidity, stage, subsite, surgical margins, facility type, and treatment modality. RESULTS: A total of 10,052 patients met inclusion criteria; 2037 (20.3%) had LVI. Mean follow-up was 70 ± 46 months. LVI was independently associated with worse OS (HR 1.22, 95% CI 1.13-1.32, p < 0.001), persisting in glottic (HR 1.30, p = 0.001) and supraglottic (HR 1.26, p < 0.001) tumors. Landmark analyses demonstrated temporal variation, with LVI remaining significantly associated with worse OS beyond 24 months of follow-up (HR 1.18, p = 0.001). Among patients with LVI, PORT and POCRT were associated with improved survival compared with surgery alone. CONCLUSION: LVI is an adverse prognostic factor associated with reduced survival in LSCC, with prognostic impact varying over time. Its integration into postoperative risk assessment may help inform adjuvant therapy selection and postoperative stratification.

来源:Laryngoscope,查看原文。版权归原作者所有。

引用

  1. Porto-Gutierrez F, Kacin A, Campbell B, et al. Lymphovascular Invasion Predicts Survival in Laryngeal Cancer: A National Database Analysis. Laryngoscope. 2026. PMID: 42760601. doi:10.1002/lary.70895

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。